SG10201911243WA - Compositions and methods for inhibiting arginase activity - Google Patents

Compositions and methods for inhibiting arginase activity

Info

Publication number
SG10201911243WA
SG10201911243WA SG10201911243WA SG10201911243WA SG10201911243WA SG 10201911243W A SG10201911243W A SG 10201911243WA SG 10201911243W A SG10201911243W A SG 10201911243WA SG 10201911243W A SG10201911243W A SG 10201911243WA SG 10201911243W A SG10201911243W A SG 10201911243WA
Authority
SG
Singapore
Prior art keywords
compositions
methods
arginase activity
inhibiting arginase
inhibiting
Prior art date
Application number
SG10201911243WA
Inventor
Eric Sjogren
Jim Li
Lijing Chen
Roland Billedeau
Timothy Stanton
Zandt Michael Van
Darren Whitehouse
Gunnar Jagdmann
Lene Petersen
Francesco Parlati
Matthew Gross
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201911243W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of SG10201911243WA publication Critical patent/SG10201911243WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG10201911243WA 2016-12-22 2017-12-22 Compositions and methods for inhibiting arginase activity SG10201911243WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662438092P 2016-12-22 2016-12-22
US201662439614P 2016-12-28 2016-12-28

Publications (1)

Publication Number Publication Date
SG10201911243WA true SG10201911243WA (en) 2020-02-27

Family

ID=60972528

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201911243WA SG10201911243WA (en) 2016-12-22 2017-12-22 Compositions and methods for inhibiting arginase activity
SG10201911240PA SG10201911240PA (en) 2016-12-22 2017-12-22 Compositions and methods for inhibiting arginase activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201911240PA SG10201911240PA (en) 2016-12-22 2017-12-22 Compositions and methods for inhibiting arginase activity

Country Status (32)

Country Link
US (4) US10287303B2 (en)
EP (2) EP3559009B1 (en)
JP (2) JP7018949B2 (en)
KR (1) KR102579849B1 (en)
CN (2) CN114989205A (en)
AU (2) AU2017382405B2 (en)
BR (1) BR112019012589B1 (en)
CA (1) CA3046987A1 (en)
CL (1) CL2019001711A1 (en)
CO (1) CO2019007839A2 (en)
CR (1) CR20190339A (en)
CY (1) CY1124483T1 (en)
DK (2) DK3842442T3 (en)
EC (1) ECSP19045511A (en)
ES (1) ES2881395T3 (en)
HR (1) HRP20210848T1 (en)
HU (1) HUE054272T2 (en)
IL (2) IL292677A (en)
LT (1) LT3559009T (en)
MD (1) MD3559009T2 (en)
MX (2) MX2019007471A (en)
MY (1) MY197478A (en)
NZ (1) NZ754364A (en)
PE (1) PE20191541A1 (en)
PH (1) PH12019501396A1 (en)
PL (1) PL3559009T3 (en)
PT (1) PT3559009T (en)
RS (1) RS61996B1 (en)
SG (2) SG10201911243WA (en)
SI (1) SI3559009T1 (en)
TW (1) TWI818902B (en)
WO (1) WO2018119440A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
RS63762B1 (en) 2015-11-19 2022-12-30 Incyte Corp Heterocyclic compounds as immunomodulators
KR20180100585A (en) 2015-12-22 2018-09-11 인사이트 코포레이션 Heterocyclic compounds as immunomodulators
ES2906460T3 (en) 2016-05-06 2022-04-18 Incyte Corp Heterocyclic compounds as immunomodulators
TW201808902A (en) 2016-05-26 2018-03-16 美商英塞特公司 Heterocyclic compounds as immunomodulators
AU2017281285C1 (en) 2016-06-20 2022-05-12 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
PT3558990T (en) * 2016-12-22 2022-11-21 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
MA47120A (en) 2016-12-22 2021-04-28 Incyte Corp PYRIDINE DERIVATIVES USED AS IMMUNOMODULATORS
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
PE20191532A1 (en) 2016-12-22 2019-10-23 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
DK3842442T3 (en) * 2016-12-22 2024-02-05 Prec Pharmaceuticals Inc Compositions and methods for inhibiting arginase activity
CN108322295B (en) 2017-01-17 2021-12-24 维沃移动通信有限公司 Sending method, receiving method, sending end and receiving end of sideband information
WO2019159120A1 (en) 2018-02-17 2019-08-22 Astrazeneca Ab Arginase inhibitors and methods of use thereof
PL3774843T3 (en) 2018-03-29 2022-11-14 Molecure Sa Dipeptide piperidine derivatives
BR112020022936A2 (en) 2018-05-11 2021-02-02 Incyte Corporation tetrahydro-imidazo [4,5-c] pyridine derivatives as pd-l1 immunomodulators
CA3109100A1 (en) 2018-08-22 2020-02-27 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EP3897622A4 (en) * 2018-12-18 2022-09-28 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
DK3921033T3 (en) * 2019-02-08 2023-10-16 Astrazeneca Ab ARGINASE INHIBITORS AND METHODS OF USING THEREOF
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CN110759843A (en) * 2019-09-30 2020-02-07 东北师范大学 Preparation and application of fluorine azide substituted quaternary heterocyclic compound
CN110734456A (en) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 compounds, preparation method and medical application thereof
WO2021096849A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11780840B2 (en) 2020-07-02 2023-10-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022016195A1 (en) * 2020-07-17 2022-01-20 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
CN112387262B (en) * 2020-11-10 2021-12-07 泰州学院 Preparation method of chiral stationary phase based on photocatalytic cross-linked protein, chiral stationary phase and application
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (en) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 Arginase inhibitors and methods of use thereof
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
WO2023133505A2 (en) * 2022-01-07 2023-07-13 The Trustees Of Columbia University In The City Of New York Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia
TW202337453A (en) 2022-03-17 2023-10-01 美商英塞特公司 Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
CN1762381B (en) 1997-07-29 2012-07-11 爱尔康实验室公司 Ophthalmic compositions containing galactomannan polymers and borate
CA2305703A1 (en) 1997-10-10 1999-04-22 David W. Christianson Compositions and methods for inhibiting arginase activity
CA2318920A1 (en) 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6720188B2 (en) 2000-07-06 2004-04-13 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP2113246B1 (en) 2003-08-07 2016-06-22 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
US20070203140A1 (en) 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
EP2064207B1 (en) 2006-09-19 2013-11-06 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008058178A1 (en) 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
MY188335A (en) 2006-11-22 2021-11-30 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
CN101932325B (en) 2007-11-30 2014-05-28 新联基因公司 Ido inhibitors
WO2011116299A2 (en) 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
JP2011518841A (en) 2008-04-24 2011-06-30 ニューリンク ジェネティクス， インコーポレイテッド IDO inhibitor
US8088803B2 (en) 2008-07-08 2012-01-03 Incyte Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
JP2012515799A (en) 2009-01-26 2012-07-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Arginase inhibitors and methods of use
WO2011082245A2 (en) 2009-12-31 2011-07-07 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2011242794B2 (en) 2010-04-22 2016-11-24 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
PL2563771T3 (en) 2010-04-24 2016-06-30 Viamet Pharmaceuticals Nc Inc Metalloenzyme inhibitor compounds
ES2789177T3 (en) * 2010-08-10 2020-10-26 Melinta Therapeutics Inc Cyclic boronic acid ester derivatives, process for their preparation and therapeutic uses thereof
KR20130110163A (en) 2010-08-27 2013-10-08 메르크 파텐트 게엠베하 Triazolopyrazine derivatives
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
EP2632903A4 (en) 2010-10-28 2014-11-26 Viamet Pharmaceuticals Inc Metalloenzyme inhibitor compounds
EA024197B1 (en) 2010-11-13 2016-08-31 Иннокрин Фармасьютикалс, Инк. Metalloenzyme inhibitor compounds
EA201390876A1 (en) 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. METALLIC ENZYME INHIBITING COMPOUNDS
EP2658580A4 (en) 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc Arginase inhibitors and methods of use thereof
NO2694640T3 (en) 2011-04-15 2018-03-17
CA2839691A1 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US8809378B2 (en) 2011-06-19 2014-08-19 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US8883797B2 (en) 2011-06-23 2014-11-11 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2012300275A1 (en) 2011-08-30 2014-03-06 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN104244932B (en) 2011-10-19 2017-02-22 马尔斯公司 Inhibitors of arginase and their therapeutic applications
EP2768509B1 (en) * 2011-10-20 2017-03-22 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2788343B1 (en) 2011-12-11 2018-02-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
IN2014DN06792A (en) 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
CN104066734B (en) 2012-01-28 2017-03-29 默克专利股份公司 Triazol [4,5 d] pyrimidine derivatives
US9120804B2 (en) 2012-02-21 2015-09-01 Merck Patent Gmbh 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
AU2012370450B2 (en) 2012-02-21 2017-02-02 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
US20150051202A1 (en) 2012-03-07 2015-02-19 Merck Patent Gmbh Triazolopyrazine derivatives
IN2014DN09678A (en) 2012-04-18 2015-07-31 Mars Inc
ES2618004T3 (en) 2012-08-07 2017-06-20 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
US20150246898A1 (en) 2012-09-12 2015-09-03 Dow Agrosciences Llc Metalloenzyme inhibitor compounds
US9663488B2 (en) 2013-01-28 2017-05-30 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
ES2636936T3 (en) 2013-03-05 2017-10-10 Merck Patent Gmbh Triazolo [4,5-d] pyrimidine derivatives for the treatment of diseases such as cancer
CA2903901A1 (en) 2013-03-05 2014-09-12 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
US9617272B2 (en) 2013-03-14 2017-04-11 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
EA201591610A1 (en) 2013-03-14 2015-12-30 Курадев Фарма Прайвит Лтд. KINURENIN PATH INHIBITORS
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
CN105324362B (en) 2013-03-15 2017-05-24 百时美施贵宝公司 Ido inhibitors
CA2905452A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (ido)
EP2994471B1 (en) 2013-05-06 2017-05-17 Merck Patent GmbH Macrocycles as kinase inhibitors
CA2913914C (en) 2013-05-28 2018-03-20 Viamet Pharmaceuticals, Inc. Fungicidal compositions
ES2719327T3 (en) 2013-07-01 2019-07-09 Bristol Myers Squibb Co IDO inhibitors
CA2917964A1 (en) 2013-07-11 2015-01-15 Bristol-Myers Squibb Company Ido inhibitors
US10821178B2 (en) 2013-07-29 2020-11-03 Board Of Regents Of The University Of Nebraska Methods of treating biofilm infections comprising administering inhibitors of myeloid-derived suppressor cells
WO2015031295A1 (en) 2013-08-27 2015-03-05 Bristol-Myers Squibb Company Ido inhibitors
BR112016009200A8 (en) 2013-10-25 2020-03-24 Pharmacyclics Llc use of a btk inhibitor and a checkpoint immune inhibitor
ES2799582T3 (en) 2013-11-08 2020-12-18 Incyte Holdings Corp Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
KR20160108568A (en) 2014-02-04 2016-09-19 인사이트 코포레이션 Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
JP6532480B2 (en) 2014-04-15 2019-06-19 ダウ アグロサイエンシィズ エルエルシー Metalloenzyme inhibitor compounds as fungicides
EP3131399A4 (en) 2014-04-15 2018-02-14 Dow AgroSciences LLC Metalloenzyme inhibitor compounds as fungicides
MX2016015610A (en) 2014-06-06 2017-07-13 Flexus Biosciences Inc Immunoregulatory agents.
TW201619133A (en) 2014-08-21 2016-06-01 裘拉德製藥私人有限公司 Novel IMINONITRILE derivatives
SG10201804868PA (en) 2014-09-05 2018-07-30 Merck Patent Gmbh Compounds for the inhibition of indoleamine-2,3-dioxygenase
CN105879030A (en) 2014-09-30 2016-08-24 复旦大学 Synergistic drug compound for treating tumor and preparation method thereof
GB201417369D0 (en) 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
GB201418300D0 (en) 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
CN107205970A (en) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 Immunomodulator
UY36390A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR102537A1 (en) 2014-11-05 2017-03-08 Flexus Biosciences Inc IMMUNOMODULATING AGENTS
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
CN107405404A (en) 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 The purposes of suramin and arginase inhibitor in malignant tumour
TWI714567B (en) 2015-04-03 2021-01-01 美商英塞特公司 Heterocyclic compounds as lsd1 inhibitors
AU2016243937A1 (en) 2015-04-03 2017-11-23 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
TW201705955A (en) 2015-05-14 2017-02-16 輝瑞大藥廠 Combination therapies comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-PD1/anti-PD-L1 antibody
WO2016196890A1 (en) 2015-06-04 2016-12-08 Vtv Therapeutics Llc Inhibitors of hexokinase and methods of use thereof
EP3313410A4 (en) 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
MD3368541T2 (en) * 2015-10-30 2020-09-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
DK3842442T3 (en) * 2016-12-22 2024-02-05 Prec Pharmaceuticals Inc Compositions and methods for inhibiting arginase activity

Also Published As

Publication number Publication date
ES2881395T3 (en) 2021-11-29
NZ754364A (en) 2023-04-28
MY197478A (en) 2023-06-19
PT3559009T (en) 2021-05-04
CA3046987A1 (en) 2018-06-28
US10287303B2 (en) 2019-05-14
MX2020013649A (en) 2021-02-26
DK3559009T3 (en) 2021-05-03
IL267532A (en) 2019-08-29
MD3559009T2 (en) 2021-07-31
SI3559009T1 (en) 2021-08-31
EP3842442A1 (en) 2021-06-30
WO2018119440A1 (en) 2018-06-28
US20200339607A1 (en) 2020-10-29
HRP20210848T1 (en) 2021-07-09
IL292677A (en) 2022-07-01
EP3559009A1 (en) 2019-10-30
SG10201911240PA (en) 2020-02-27
US20210261573A1 (en) 2021-08-26
AU2022201072A1 (en) 2022-03-10
CR20190339A (en) 2020-01-10
AU2017382405B2 (en) 2021-12-16
CN110382508B (en) 2022-08-02
JP2022066199A (en) 2022-04-28
US11021495B2 (en) 2021-06-01
BR112019012589A2 (en) 2019-11-19
ECSP19045511A (en) 2019-10-31
TWI818902B (en) 2023-10-21
CN110382508A (en) 2019-10-25
CL2019001711A1 (en) 2020-01-17
US10597411B2 (en) 2020-03-24
KR20190119579A (en) 2019-10-22
US20180222926A1 (en) 2018-08-09
PE20191541A1 (en) 2019-10-23
BR112019012589B1 (en) 2022-11-29
US20190330244A1 (en) 2019-10-31
CN114989205A (en) 2022-09-02
CY1124483T1 (en) 2022-07-22
AU2017382405A1 (en) 2019-06-27
CO2019007839A2 (en) 2019-10-21
JP7018949B2 (en) 2022-02-14
DK3842442T3 (en) 2024-02-05
JP2020514271A (en) 2020-05-21
EP3842442B1 (en) 2023-11-01
HUE054272T2 (en) 2021-09-28
PH12019501396A1 (en) 2019-12-02
KR102579849B1 (en) 2023-09-18
TW201828948A (en) 2018-08-16
LT3559009T (en) 2021-06-25
PL3559009T3 (en) 2021-10-25
MX2019007471A (en) 2019-11-05
EP3559009B1 (en) 2021-04-07
RS61996B1 (en) 2021-07-30
IL267532B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
IL267532B (en) Compositions and methods for inhibiting arginase activity
IL288225A (en) Compositions and methods for inhibiting arginase activity
ZA201800328B (en) Compositions and methods for inhibiting arginase activity
HK1257295A1 (en) Compositions and methods for immunooncology
HK1251610A1 (en) Compositions and methods for inhibiting factor d
HK1252911A1 (en) Compositions and methods for inhibiting the biological activity of soluble biomolecules
HK1245158A1 (en) Apilimod compositions and methods for using same
HK1254550A1 (en) Compositions and methods for inhibiting beta-lactamase
IL252191B (en) Compositions and methods for modulating at2r activity
GB201521083D0 (en) Compositions for treatment and methods thereof